One To Watch

Abcuro

A US-based clinical-stage biotechnology company developing first-in-class immunotherapies designed to deplete highly cytotoxic T cells in autoimmune diseases and certain cancers. Abcuro’s strategy centers on precise modulation of cytotoxic and NK cell populations through monoclonal antibody programs, with lead assets advancing toward registrational trials in rare disease settings.

Company Overview

Abcuro is focused on the development of targeted immunotherapies that selectively remove pathogenic cytotoxic T cells while sparing regulatory and memory T cells, aiming to treat debilitating autoimmune diseases and difficult-to-manage lymphocytic malignancies.

The company’s lead candidate, ulviprubart (also known as ABC008), is a first-in-class anti-KLRG1 monoclonal antibody designed to selectively deplete KLRG1-positive highly cytotoxic cells implicated in tissue damage.

Abcuro is also exploring other indications and potential expansions where similar cytotoxic T-cell biology plays a role.


Headquarters and Global Presence

Abcuro is headquartered in Newton, Massachusetts, United States.

The company operates primarily as a development-stage biotech, relying on external clinical networks and specialist investigators to advance its programs.


Founding and History

Abcuro was founded in 2015 and has since raised significant venture capital to support its immunotherapy pipeline.

The company has advanced through Series A, Series B and a large Series C financing, with the most recent $200 million Series C led by New Enterprise Associates and Foresite Capital to fund the registrational Phase II/III MUSCLE trial in inclusion body myositis and preparation for a potential Biologics License Application (BLA).


Therapy Areas and Focus

Abcuro’s core focus areas are:

  • Autoimmune disease with a cytotoxic T-cell component, notably inclusion body myositis (IBM)
  • Rare hematologic autoimmune disorders such as T cell large granular lymphocytic leukemia (T-LGLL)
  • Mature T and NK cell lymphomas where KLRG1-expressing cells may be malignant
  • Additional autoimmune disorders where highly cytotoxic T cells contribute to pathology


Technology Platforms and Modalities

Abcuro’s pipeline centers on selective depletion of highly cytotoxic T and NK cells through monoclonal antibodies targeting killer cell lectin-like receptor G1 (KLRG1).

The underlying rationale is that KLRG1 is expressed on late-differentiated effector T cells that drive tissue damage, making it a compelling target for precision immune modulation.


Key Personnel

  • Alex Martin – Chief Executive Officer (appointed October 2022)
  • H. Jeffrey Wilkins, M.D. – Chief Medical Officer (appointed June 2022)
  • George Eldridge – Chief Financial Officer (appointed August 2025)
  • Courtney Cupples – Chief Commercial Officer (appointed June 2025)
  • Mark Pruzanski, M.D. – Chairman of the Board (appointed December 2023)


Strategic Partnerships

Abcuro works with venture capital partners and strategic investors to fund its development. Its Series C financing round was led by New Enterprise Associates and included participation from Foresite Capital and existing backers such as RA Capital Management, Bain Capital Life Sciences and Sanofi Ventures, among others.

The company’s development model is internally driven, with potential for external collaborations as programs near regulatory milestones.


FAQ Section

Abcuro is a clinical-stage biotech developing immunotherapies that precisely deplete highly cytotoxic T cells implicated in autoimmune disease and lymphoid malignancies. Its strategy is built around selective immune modulation via antibodies targeting KLRG1.

The company prioritizes autoimmune conditions driven by cytotoxic T cells such as inclusion body myositis and T cell large granular lymphocytic leukemia, as well as mature T and NK cell lymphomas where pathogenic KLRG1-expressing cells are relevant.

The lead program is ulviprubart (ABC008), a monoclonal antibody targeting KLRG1 designed to selectively deplete highly cytotoxic T cells in autoimmune disease and certain cancers. It is being evaluated in Phase II/III registrational trials and Phase I/II studies in rare hematologic conditions.

Recent topline results from the Phase II/III MUSCLE study in inclusion body myositis showed a favorable safety and tolerability profile for ulviprubart and clinically meaningful slowing of disease progression in patients with mild to moderate disease, supporting advancement in that population.

Key watchpoints include completion and readout of the registrational Phase II/III MUSCLE trial in IBM, potential BLA filing strategy, and progression decisions for ulviprubart in hematologic autoimmune disorders.

Abcuro’s KLRG1 targeting aims to deplete pathogenic cytotoxic T and NK cells specifically, rather than broadly suppressing the immune system, potentially preserving regulatory and memory cell populations while reducing tissue-destructive cells.

The next key milestones are topline Phase II/III MUSCLE trial results in inclusion body myositis, regulatory alignment and potential BLA filing readiness, as well as data from Phase I/II studies in T-LGLL and lymphomas that could expand indication breadth.

Want to Update your Company's Profile?


More Abcuro news >